3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
3
Recruiting
2
Withdrawn
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
24
Carcinoma, Renal Cell
15
Carcinoma, Non-Small-Cell Lung
15
Neoplasm Metastasis
12
Urinary Bladder Neoplasms
6
Sarcoma
6
Prostatic Neoplasms
6
Lung Neoplasms
6
Pancreatic Neoplasms
5
Neoplasms
5
Kidney Neoplasms
5
Ovarian Neoplasms
4
Glioblastoma
4
Carcinoma, Transitional Cell
4
Uveal Melanoma
3
Small Cell Lung Carcinoma
3
Myelodysplastic Syndromes
3
Mesothelioma
3
Histiocytoma, Malignant Fibrous
3
Colorectal Neoplasms
3
Chordoma
3
Carcinoma, Neuroendocrine
3
Carcinoma, Merkel Cell
3
Breast Neoplasms
3
Brain Neoplasms
3
Urogenital Neoplasms
2
Urethral Neoplasms
2
Ureteral Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Interventions
Cisplatin
10
pembrolizumab
8
Carboplatin
8
Paclitaxel
6
durvalumab
5
Pemetrexed
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
osimertinib
4
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
Taxes
3
Nivolumab
3
Gemcitabine
3
Docetaxel
3
Bevacizumab
3
cabozantinib
2
atezolizumab
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiation
2
Platinum
2
Immunoglobulin G
2
Disulfides
2
CP protocol
2
Biopsy
2
1,2-diaminocyclohexaneplatinum II citrate
2
trifluridine tipiracil drug combination
1
tremelimumab
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma
×
Ipilimumab
×
Clear all
NCT03937219
2025-09-10
COSMIC-313
Exelixis
Phase 3
Active not recruiting
855 enrolled
12 charts